Identification of Active Compounds Sample Clauses

Identification of Active Compounds. Promptly after completing the screening of a batch of compounds under this Section 5.1 in the appropriate assays, the Parties will provide to the Research Management Committee the results of such screening. The Research Management Committee will review such results promptly after receipt and will determine which of the screened compounds meet the requirements established by the Research Management Committee for identification as Active Compounds. Upon identifying Active Compounds, the Research Management Committee shall add such compounds to the list of all Active Compounds, which shall be maintained by the Research Management Committee, and shall forward the updated list to each Party.
Sample 1Sample 2
AutoNDA by SimpleDocs
Identification of Active Compounds. During the Research Term, the parties shall collaborate in accordance with the Research Plan to perform research to identify Active Compounds with the potential to become Allergan Designated Compounds or ACADIA Designated Compounds. The parties shall report the results of such research promptly to the RMC.
Sample 1Sample 2
Identification of Active Compounds. Promptly after completing the screening of a batch of compounds under this Section 4.2 in the appropriate Target Assays, SUGEN will provide to the RMC the results of such screening. The RMC will review such Target Assay results promptly after receipt and will determine which of the screened compounds meet the requirements established by the RMC for identification as Active Compounds. Upon identifying Active Compounds, the RMC shall add such compounds to the list of all Active Compounds, which shall be maintained by the RMC, and shall forward the updated list to each party. SUGEN will promptly provide to the RMC any information in SUGEN's possession regarding the chemical structure and properties of Active Compounds.
Sample 1
Identification of Active Compounds. ArQule hereby grants Cubist a nonexclusive, worldwide license (without the right to sublicense) under, the ArQule Patent Rights and other rights in ArQule Technology to screen the delivered Mapping Array compounds against any Targets in the Field. Cubist agrees to screen the delivered Mapping Array compounds expeditiously and in a scientifically sound manner. Cubist shall promptly disclose to ArQule the array plate number and well number of any Active Compounds. ArQule will promptly determine whether the Active Compounds are Available Compounds and notify Cubist of such determination. If an Active Compound is not an Available Compound, Cubist shall have no rights with respect to that Active Compound. For Available Active Compounds, ArQule shall disclose to Cubist the chemical composition and structure of those Active Compounds, and Cubist shall disclose to ArQule the identity of the Target, level of activity, and a description of the primary assays used to detect the activity. All such information disclosed by ArQule and Cubist shall be deemed Confidential Information and, as such, is subject to the restrictions set forth in Article 6.
Sample 1
Identification of Active Compounds. Initially, ArQule will not identify the structures of the individual ArQule Compounds. Searxx xxx screen the ArQule Compounds against any Targets within the Field during the term of this Agreement. If Searxx xxxects any Active Compound, Searxx xxxll disclose to ArQule the location of the Active Compound in the Compass Array Library or Mapping Array, and ArQule shall determine whether such Active Compound is an Available Compound as soon as reasonably practicable, but no later than [*] after such request if the request is for not more than [*] ArQule Compounds within any period of [*]. During the period in which ArQule determines whether an ArQule Compound is an Available Compound, ArQule shall tentatively reserve for Searxx xx an exclusive basis such ArQule --------------- *Confidential treatment has been requested for the marked portion.
Sample 1
Identification of Active Compounds. Each Party will inform the other Party's members on the JRC in writing as promptly as practicable upon the Party's discovery, synthesis, acquisition or identification of Active Compounds during the Research Term and (in the case of Axys) during the license period set forth in Section 3.1(a)(ii). The notifying Party will include in such notices the structure of such Active Compounds and the assay information showing the required functional criteria as provided in Section 1.1(a).
Sample 1
Identification of Active Compounds. Promptly after completing the testing of a batch of compounds under this Section 4.1 in the Assays, ACADIA will provide to the RMC the results of such testing. The RMC will review such Assay results promptly after receipt and will determine which of the screened compounds meet the requirements established in the Research Plan for designation as Active Compounds, as such requirements may be modified by the RMC. Upon designating Active Compounds, the RMC shall add such compounds to the list of all Active Compounds, which shall be maintained by the RMC, and shall forward the updated list to each party.
Sample 1
AutoNDA by SimpleDocs
Identification of Active Compounds. Initially, ArQule will not identify the structures of the individual ArQule Compounds. Monsanto may screen the ArQule Compounds against any Targets within the Field during the term of this Agreement. If Monsanto detects any Active Compound, Monsanto shall disclose to ArQule the location of the Active Compound in the Compass Array Library or Mapping Array, and ArQule shall determine whether such Active Compound is an Available Compound as soon as reasonably practicable, but no later than [*] after such request if the request is for not more than [*] ArQule Compounds within any period of [*]. During the period in which ArQule determines whether an ArQule Compound is an Available Compound, ArQule shall tentatively reserve for Monsanto on an exclusive basis such ArQule Compound pending its determination. If an Active Compound is not an Available Compound, then ArQule shall not disclose the structure of such Active Compound and such Active Compound may not be designated as a Licensed Compound under this Agreement. If an Active Compound is an Available Compound, then subject to confirmation of significant functional activity by the Research Committee (which confirmation will occur as soon as reasonably practicable but not more than [*] after Monsanto furnishes the confirmatory data to the Research Committee), ArQule will disclose (i) the full structure of the Active Compound correlated to the well location, (ii) [*] and (iii) if the Active Compound is identified in a Mapping Array, the structures, but not the locations in the Mapping Array, of the inactive ArQule Compounds that Monsanto has screened from the same Mapping Array, and ArQule shall reserve to Monsanto the Active Compound and up to [*] Active Homologs that are Available Compounds. All such disclosed information shall be treated as Confidential Information by the Receiving Party. ArQule shall furnish Monsanto with up to [*] resynthesized Active Compounds per month in quantities of not less than [*], as directed by the Research Committee, [*] and additional resynthesized Active Compounds in quantities of not less than [*], as directed by the Research Committee, at a cost of [*]. ArQule shall maintain the compound reservation for a period of [*] after Monsanto receives the resynthesized Active Compound. Monsanto may extend the [*] reservation period for not more than [*] Active Compounds at the same time, subject to increase by the Research Committee. Monsanto may subsequently request that the Research ...
Sample 1
Identification of Active Compounds 
Sample 1

Related to Identification of Active Compounds

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Extracurricular Activities Effective July 1, 2009, stipends for participation in extracurricular activities which are authorized by the appointing authority shall be: Inland $950/year Sailing $400/year Art Club Advisor $300/year Drama Club Advisor $300/year Cross Country Skiing $150/year Boys’ Basketball $1000/year Girls’ Basketball (if class D) $1000/year Asst. Boys’ Basketball $750/year Asst. Girls’ Basketball (if class D) $750/year Scorekeeper/Timekeeper $10/game Soccer $400/year Track $400/year Cross County Running $400/year Girls’ Basketball (if not class D) $400/year Sports Activity Director $400/year Athletic Director $200/year

  • EXTRA-CURRICULAR ACTIVITIES 1. In this Agreement, extra-curricular programs and activities include all those that are beyond the provincially prescribed and locally determined curricula of the school district. 2. The Board and the Association consider it desirable that teachers participate in extra-curricular activities, and recognize that participation in extra-curricular activities by the individual teacher is on a voluntary basis.

  • Scope of Collaboration As part of the collaboration, the Controllers will act as Joint Controller. The roles of the Controller and the associated tasks are specified in more detail in Appendix 1. If one party is solely responsible for a data processing operation, this party will implement all relevant data protection provisions on its own responsibility. However, such data processing procedures are not subject to this Agreement. Joint data processing and the type of Personal Data collected and processed within the framework of collaboration are specified in Appendix 1.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Product Testing No later than [**] prior to a scheduled Delivery ARIAD US shall send to ARIAD SWISSCO the Delivery Documents for review. Following such review, unless within [**] of receipt of the Delivery Documents ARIAD SWISSCO gives written notice of rejection of the Product to be delivered, stating the reasons for such rejection, the Delivery shall proceed, and both Parties shall organize the same. Upon arrival at ARIAD SWISSCO nominated site it shall visually inspect the shipment of the Product to identify any damage to the external packaging. ARIAD SWISSCO may reject any shipment (or portion thereof) of the Product that is damaged by providing to ARIAD US reasonable evidence of damage within [**] after Delivery of such Product. If ARIAD SWISSCO does not so reject any shipment (or portion thereof) of the Product within [**] of Delivery of such Product, ARIAD SWISSCO shall be deemed to have accepted such shipment of the Product; provided, however, that in the case of the Product having any Latent Defect, ARIAD SWISSCO shall notify ARIAD US promptly once it becomes aware that a Product contains a Latent Defect and subsequently may reject such Product by giving written notice to ARIAD US of ARIAD SWISSCO’s rejection of such Product and shipping a representative sample of such Product or other evidence of Non-Conformance to ARIAD US within [**] after becoming aware of such Latent Defect, which notice shall include a description of the Latent Defect.

  • Application of Funding Techniques to Programs 6.3.1 The State shall apply the following funding techniques when requesting Federal funds for the component cash flows of the programs listed in sections 4.2 and 4.3 of this Agreement. 6.3.2 Programs Below are programs listed in Section 4.2 and Section 4.3.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!